Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy

JACC Cardiovasc Interv. 2013 Feb;6(2):182-4. doi: 10.1016/j.jcin.2012.10.007.

Authors

José Luis Ferreiro¹, Masafumi Ueno, Antonio Tello-Montoliu, Salvatore D Tomasello, Naveen Seecheran, Bhaloo Desai, Fabiana Rollini, Luis A Guzman, Theodore A Bass, Dominick J Angiolillo

Affiliation

¹ University of Florida College of Medicine-Jacksonville, Jacksonville, Florida 32209, USA.

PMID: 23428011
DOI: 10.1016/j.jcin.2012.10.007

No abstract available

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Acute Coronary Syndrome / blood
Acute Coronary Syndrome / therapy*
Adenosine Diphosphate
Biomarkers / blood
Blood Platelets / drug effects*
Blood Platelets / metabolism
Cell Adhesion Molecules / blood
Chi-Square Distribution
Drug Administration Schedule
Drug Resistance
Humans
Microfilament Proteins / blood
Percutaneous Coronary Intervention* / adverse effects
Phosphoproteins / blood
Phosphorylation
Piperazines / administration & dosage*
Piperazines / adverse effects
Platelet Aggregation / drug effects
Platelet Aggregation Inhibitors / administration & dosage*
Platelet Aggregation Inhibitors / adverse effects
Platelet Function Tests
Prasugrel Hydrochloride
Prospective Studies
Purinergic P2Y Receptor Antagonists / administration & dosage*
Purinergic P2Y Receptor Antagonists / adverse effects
Receptors, Purinergic P2Y12 / blood
Receptors, Purinergic P2Y12 / drug effects
Thiophenes / administration & dosage*
Thiophenes / adverse effects
Time Factors
Treatment Outcome

Substances

Biomarkers
Cell Adhesion Molecules
Microfilament Proteins
P2RY12 protein, human
Phosphoproteins
Piperazines
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Receptors, Purinergic P2Y12
Thiophenes
vasodilator-stimulated phosphoprotein
Adenosine Diphosphate
Prasugrel Hydrochloride